Cargando…
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study
Hetrombopag, a small molecular thrombopoietin-receptor agonist, has shown encouraging efficiency in immunosuppressive therapy refractory or relapsed severe aplastic anaemia. To investigate the response rate of hetrombopag combined with IST as first-line treatment, we designed a prospective pilot stu...
Autores principales: | Yang, Wenrui, Zhao, Xin, Liu, Xu, Xiong, Youzhen, Fan, Huihui, Zhang, Li, Li, Jianping, Ye, Lei, Zhou, Kang, Li, Yuan, Yang, Yang, Peng, Guangxin, Jing, Liping, Zhang, Fengkui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890734/ https://www.ncbi.nlm.nih.gov/pubmed/36726169 http://dx.doi.org/10.1186/s40164-023-00377-3 |
Ejemplares similares
-
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study
por: Yang, Wenrui, et al.
Publicado: (2023) -
P792: CLINICAL STUDY OF HETROMBOPAG COMBINED WITH CYCLOSPORINE A IN THE TREATMENT OF CHILDREN WITH NON-SEVERE APLASTIC ANEMIA
por: Chang, Lixian, et al.
Publicado: (2023) -
PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY
por: Gong, Yuemin, et al.
Publicado: (2023) -
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
por: Peng, Guangxin, et al.
Publicado: (2022) -
Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia
por: Liu, Xu, et al.
Publicado: (2023)